Who are Lifitegrast 5% Ophthalmic Solution's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lifitegrast-5-ophthalmic-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Lifitegrast 5% Ophthalmic Solution — Competitive Intelligence Brief

Lifitegrast 5% Ophthalmic Solution (Lifitegrast 5% Ophthalmic Solution) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: LFA-1 antagonist. Area: Ophthalmology.

marketed LFA-1 antagonist LFA-1 (lymphocyte function-associated antigen-1) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Lifitegrast 5% Ophthalmic Solution (Lifitegrast 5% Ophthalmic Solution) — Research Insight LLC. Lifitegrast is a lymphocyte function-associated antigen-1 (LFA-1) antagonist that blocks T-cell adhesion and infiltration into ocular tissues to reduce inflammation in dry eye disease.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lifitegrast 5% Ophthalmic Solution TARGET	Lifitegrast 5% Ophthalmic Solution	Research Insight LLC	marketed	LFA-1 antagonist	LFA-1 (lymphocyte function-associated antigen-1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (LFA-1 antagonist class)

Research Insight LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lifitegrast 5% Ophthalmic Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/lifitegrast-5-ophthalmic-solution. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab